Research
Hormonal
Gastric bypass surgery leads to sustained weight loss, partly mediated by a decrease in circulating ghrelin and an increase in peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) levels.
Gastric bypass surgery causes sustained weight loss, partly by altering gut hormones (lower ghrelin, higher PYY/GLP-1). This hormonal shift offers a model for developing non-surgical obesity treatments that replicate this profile.
GoodSupportsHIGH confidence
Although the mechanism of long-term weight loss following bariatric surgery is yet to be determined, several gut hormones have been implicated. For example, a decrease in circulating ghrelin and an increase in peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) levels have been found following bypass surgery [15-17].
Why this rating
The paper cites multiple studies ([15-17]) linking surgery to hormone changes, though it notes the exact mechanism is 'yet to be determined'.
Source
The role of gut hormones and the hypothalamus in appetite regulation
Keisuke Suzuki et al. · Endocrine Journal · 2010
DOI 10.1507/endocrj.k10e-077
narrative_reviewCited 315×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Peripheral administration of Peptide YY (PYY) (3-36) reduces food intake and body weight gain in rodents and reduces appetite in humans, primarily by acting on Y2 receptors in the arcuate nucleus and via vagal afferent signaling.Good
- Peripheral administration of Glucagon-like peptide-1 (GLP-1) reduces food intake in a dose-dependent manner in both normal weight and obese subjects, although obese subjects have a blunted postprandial GLP-1 response.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →